Sonnet BioTherapeutics Announces Generation And In Vitro Characterization Of Novel Drug Candidates SON-1411 And SON-1400
Portfolio Pulse from Benzinga Newsdesk
Sonnet BioTherapeutics has announced the generation and in vitro characterization of two novel drug candidates, SON-1411 and SON-1400. These candidates are based on a modified version of Interleukin-18 (IL-18BPR) and have shown promising bioactivity in receptor binding assays. SON-1411 is manufactured in CHO cells, while SON-1400 is made in E. coli. Both drugs could have broad applications in oncology and cell-based therapies.
June 13, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sonnet BioTherapeutics has announced the development of two new drug candidates, SON-1411 and SON-1400, which have shown promising bioactivity in receptor binding assays. This could potentially boost the company's stock price in the short term.
The announcement of promising new drug candidates often leads to positive investor sentiment and a potential increase in stock price. The bioactivity results and potential applications in oncology and cell-based therapies add to the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100